Dual GLP-1/Glucagon Agonist Research: Weight Loss Study

As the global obesity epidemic continues to accelerate, researchers are racing to develop more effective pharmacological tools to help patients achieve meaningful, lasting weight loss. A new class of agents — dual glucagon-like peptide-1 and glucagon receptor (GLP-1/GCGR) agonists — has emerged as a promising frontier. A comprehensive systematic review and meta-analysis published in Diabetes, Obesity & Metabolism in 2026 offers the most detailed class-specific assessment of these agents to date, suggesting they may produce significant reductions in body weight and broad metabolic improvements with an acceptable short-term safety profile (Amjad et al., 2026).

What This Study Found

The meta-analysis, conducted by Amjad and colleagues, systematically searched five major databases — PubMed, Embase, Cochrane Library, Scopus, and ClinicalTrials.gov — through July 2026, ultimately identifying 19 randomized controlled trials (RCTs) evaluating four dual GLP-1/GCGR agonists: mazdutide, survodutide, cotadutide, and efinopegdutide. All trials enrolled adults with overweight or obesity, providing a robust dataset for class-level conclusions.

Using a random-effects meta-analysis model, researchers found that dual GLP-1/GCGR agonists were associated with a statistically significant mean absolute body weight reduction of 6.65 kg compared to controls, with a corresponding relative weight reduction of approximately 7.15%. Participants receiving these agents were also nearly five times more likely to achieve a clinically meaningful threshold of 5% or greater body weight loss (Risk Ratio: 4.75), though the certainty of evidence for this outcome was rated as low.

Beyond weight, the study suggests these agents produced significant improvements across several important metabolic markers. Researchers observed meaningful reductions in HbA1c (a key indicator of long-term blood glucose control), BMI, waist circumference, systolic blood pressure, and triglyceride levels. Among the agents analyzed, mazdutide and survodutide appeared to demonstrate the largest weight loss effects.

On the safety side, individuals treated with dual GLP-1/GCGR agonists experienced any adverse events at a modestly higher rate than controls (Risk Ratio: 1.16). However, a key finding was that serious adverse events did not differ significantly from controls (Risk Ratio: 0.90), with the certainty of evidence for this outcome rated as high — offering meaningful reassurance about the short-term safety of this drug class.

Clinical Significance

To understand why this research matters, it helps to appreciate the dual mechanism these agents employ. While GLP-1 receptor agonism is already well-established as a driver of appetite suppression and improved glucose metabolism, the addition of glucagon receptor agonism introduces complementary effects, including increased energy expenditure and enhanced fat breakdown. Researchers have theorized that this combination could produce greater weight loss than GLP-1 receptor agonism alone — and this meta-analysis offers preliminary population-level evidence supporting that hypothesis.

The authors were careful to distinguish this drug class from other multi-receptor agonists currently in use or under investigation. Agents such as tirzepatide and retatrutide, which act on GIP (glucose-dependent insulinotropic polypeptide) receptors in addition to GLP-1 and/or glucagon receptors, have frequently been grouped together with pure GLP-1/GCGR agonists in prior analyses. The authors argue this conflation obscures class-specific performance, and their decision to evaluate GLP-1/GCGR agonists as a distinct category represents an important methodological contribution to the field.

The breadth of metabolic improvements observed — spanning glycemic control, blood pressure, and lipid levels — is also clinically notable. Obesity rarely exists in isolation; it frequently co-occurs with type 2 diabetes, hypertension, and dyslipidemia. The study suggests that dual GLP-1/GCGR agonists may address several of these interrelated conditions simultaneously, which could make them particularly valuable for patients managing complex cardiometabolic risk profiles.

The authors do emphasize important limitations. The evidence base is still maturing, and longer-term head-to-head trials are needed to confirm durability of effects and, critically, cardiovascular safety outcomes. The certainty of evidence varied across outcomes, ranging from high for serious adverse events to low for the ≥5% weight loss threshold, underscoring the need for continued rigorous investigation.

Current Access and Compliance Context

As of this writing, the dual GLP-1/GCGR agonists analyzed in this meta-analysis — mazdutide, survodutide, cotadutide, and efinopegdutide — are not yet approved by major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of obesity. Several are in active Phase 2 and Phase 3 clinical development, meaning the landscape of approved options in this specific drug class may change substantially in the coming years.

Patients and clinicians should be aware that currently approved GLP-1-based therapies (such as semaglutide and liraglutide) remain the established standard of care within the broader incretin-based treatment class for obesity. Dual GLP-1/GCGR agonists represent a next-generation approach that, while showing considerable promise in clinical trials, has not yet completed the full regulatory evaluation process required for widespread clinical use.

Any individual considering peptide-based therapies for weight management should do so only under the supervision of a qualified, licensed healthcare provider who can assess eligibility, monitor for adverse effects, and ensure that treatment aligns with current clinical guidelines and the individual's overall health profile.

What Patients Should Know

If you are living with overweight or obesity and have been following developments in weight management pharmacology, findings like these can feel exciting — and understandably so. A mean weight reduction of more than 6 kg, combined with improvements in blood sugar, blood pressure, and triglycerides, represents a potentially meaningful clinical benefit for many patients. However, several points deserve careful consideration before drawing personal conclusions from this research.

First, meta-analyses summarize population-level trends. Individual responses to any medication can vary significantly based on genetics, baseline health status, concomitant medications, and lifestyle factors. The average outcomes reported in a meta-analysis may not reflect what any given individual would experience.

Second, the drugs analyzed are investigational. Participating in a clinical trial or accessing an unapproved therapy through other means carries different risk considerations than receiving an FDA-approved medication with a well-established post-market safety record. Patients should have transparent conversations with their physicians about what is approved, what is investigational, and what the evidence actually says.

Third, pharmacological therapy works best as part of a comprehensive approach. Nutrition, physical activity, sleep, and behavioral support remain foundational pillars of sustainable weight management. Emerging peptide therapies are tools that may complement — but should not replace — lifestyle-based strategies.

If you are interested in learning more about peptide-based therapies and whether any currently approved or investigational options might be appropriate for your situation, speaking with a knowledgeable healthcare provider is the essential next step.

Conclusion

The 2026 meta-analysis by Amjad and colleagues represents a meaningful step forward in characterizing the class-specific efficacy and safety of dual GLP-1/GCGR agonists for obesity management. With 19 randomized controlled trials and rigorous analytical methods, the study suggests this emerging drug class may produce significant weight loss and broad metabolic improvements, with serious adverse events comparable to placebo in the short term. Longer, larger, and head-to-head trials will be essential to establish durability and cardiovascular safety before these agents can be considered for widespread clinical adoption.

The science of peptide-based therapies for metabolic health is advancing rapidly. Staying informed and working with a qualified medical professional are the most important steps any patient can take. To find a knowledgeable provider in your area who stays current with the latest evidence in peptide therapeutics, visit peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content summarizes published research and should not be used as a substitute for professional medical consultation. Always speak with a qualified and licensed healthcare provider before making any decisions about medical treatments, medications, or health interventions. The Peptide Association does not endorse any specific drug, therapy, or clinical protocol.

---

Citation (AMA Format): Amjad MM, Khan MM, Sarwar F, et al. Efficacy and safety of dual GLP-1/glucagon receptor agonism in overweight and obesity: a class-specific systematic review and meta-analysis. Diabetes Obes Metab. 2026. doi:10.1111/dom.71400. PMID: 42811393.